Overview Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD Status: Completed Trial end date: 2018-10-17 Target enrollment: Participant gender: Summary This study will evaluate the efficacy and safety of low doses of SPN-812 in adolescents 12-17 years of age. Phase: Phase 3 Details Lead Sponsor: Supernus Pharmaceuticals, Inc.